Liaoning Fuyuan Pharmaceutical Co., Ltd.

Primary Study Objective: To investigate the relative bioavailability of a single oral dose (fasting/postprandial) of the test formulation, 2.5 mg levamlodipine besylate tablets (strength: 2.5 mg/tablet, calculated as levamlodipine; manufactured by Liaoning Fuyuan Pharmaceutical Co., Ltd.) compared to a 5 mg reference formulation, amlodipine besylate tablets (trade name: Norvasc®; strength: 5 mg/tablet, calculated as amlodipine; manufactured by Huizhi Pharmaceutical (Dalian) Co., Ltd.), in healthy Chinese volunteers. The pharmacokinetic parameters of the two formulations were analyzed, and the bioequivalence of the two formulations was evaluated to provide a reference for drug application and clinical use. Secondary Study Objective: To evaluate the safety of a single oral dose (fasting/postprandial) of the test formulation, 2.5 mg levamlodipine besylate tablets, compared to a 5 mg reference formulation, amlodipine besylate tablets, in healthy Chinese adult volunteers.

Main study objectives: To investigate the pharmacokinetic characteristics of a single oral dose (fasting/postprandial) of 100 mg of the test formulation diclofenac sodium sustained-release tablets and the reference formulation VOLTAREN® in healthy adult Chinese subjects, and to preliminarily evaluate the bioequivalence and intra-individual variability of the two formulations under fasting and postprandial conditions. Secondary study objectives: To evaluate the safety of a single oral dose of 100 mg (fasting/postprandial) of the test formulation and the reference formulation in healthy adult Chinese subjects.